

Greinar í erlendum fræðiritum 2000-2009

I. Frá Leitarstöð Krabbameinsfélagsins

1. Sigurdsson K, Adalsteinsson S. Risk variables affecting high-grade Pap smears at second visit: Screening interval, year, age and low-grade smears. *Int. J. Cancer* 94, 884-888 (2001).
2. Gudmundsdóttir Th. et.al. Eligibility and willingness of young Icelandic women to participate in an HPV-trial. *Acta Gyn Obstet Scand* 83, 345-350 (2003).
3. Sigurdsson K, Sigvaldason H. Longitudinal trends in cervical cytological lesions and the effect of risk factors. A 30-year overview. *Acta Gyn Obstet Scand* 2006; 85: 350-358.
4. Sigurdsson K, Sigvaldason H. Longitudinal trends in cervical histological lesions (CIN 2-3+). A 25-year overview. *Acta Gyn Obstet Scand* 2006; 85: 359-365.
5. Sigurdsson K, Sigvaldason H. Effectiveness of cervical cancer screening in Iceland, 1964-2002: a study on trends in incidence and mortality and the effect of risk factors. *Acta Gyn Obstet Scand* 2006; 85: 343-349.
6. Sigurdsson K, Sigvaldason H. Is it rational to start population-based cervical cancer screening at age 20? Analysis of time trends in preinvasive and invasive disease. *Eur J Cancer* 2007; 43: 769-774.
7. Sigurdsson K. Cervical cancer screening-effectiveness and implications of HPV vaccines. *European Magazine on Sexual and Reproductive Health-Entre Nous-WHO publication*. 2007; 64: 16-18.
8. Gabe R. et.al. A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. *Acta Radiol* 2007; 9:948-955.
9. Sigurdsson K. et.al. HPV genotypes in CIN 2-3 lesions and cancer. A population-based study during to time periods. *Int J Cancer* 2007; 121: 2682-2687.
10. Sigurdsson K. et.al. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening. *Acta Gyn Obstet Scand* 2009; 88:22-35.

II. Frá Future II rannsóknarhópnum

Fjölbjórannsókn um gagnsemi HPV-bóluefnis (Gardasil) gegn leghálskrabbameini. 710 þátttakendur frá Íslandi. Kristján Sigurdsson ábyrgur rannsóknaraðili fyrir Ísland.

11. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. *N Engl J Med* 2007; 356: 1915-1927.
12. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *The Lancet* 2007; 369: 1861-1868.
13. The Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. *JID* 2007; 196: 1438-46.
14. The Future II Study Group. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. *Current Medical Research and Opinion (CMRO)* 2008; 24 (6):1623-1634.
15. Elmar A. Joura et.al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. *Vaccine* 2008; 26; 6844-6851.
16. Cosette M. Wheeler et.al. The impact of quadrivalent HPV (type 6/11/16/18) L1 VLP vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16-26. *JID* 2009; 199; 936-944.
17. Darron R. Brown et.al. The impact of quadrivalent HPV (type 6/11/16/18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26. *JID* 2009; 199; 926-935.
18. Majewski S. et.al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. *Journal of the European Academy of Dermatology and Venereology* 2009, 23, 1147-1155 (DOI:10.1111/j.1468-3083.2009.03266.x).